InvivoChem Cat #:V31593CAS #:217099-44-0Purity >=98%Description:BCX 1470 methanesulfonate is a novel, potent and selective Serine protease inhibitorthat inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s(IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that oftrypsin. . CX 1470 blocks the esterolytic and hemolytic activities ofthe complement enzymes Cls and factor D in vitro, also blockeddevelopment of RPA-induced edema in the rat. BCX 1470 may be useful asan anti-inflammatory agent in diseases where complement activation isknown to be detrimental.
References: The Arthus Reaction in Rodents: Species-Specific Requirement of ComplementJournal of Immunology, 2000, 164, 463-468
Related CAS#: 217099-43-9 (free base)
Description:BCX 1470 methanesulfonate is a novel, potent and selective Serine protease inhibitorthat inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s(IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that oftrypsin. . CX 1470 blocks the esterolytic and hemolytic activities ofthe complement enzymes Cls and factor D in vitro, also blockeddevelopment of RPA-induced edema in the rat. BCX 1470 may be useful asan anti-inflammatory agent in diseases where complement activation isknown to be detrimental.
References: The Arthus Reaction in Rodents: Species-Specific Requirement of ComplementJournal of Immunology, 2000, 164, 463-468
Related CAS#: 217099-43-9 (free base)